All In Biotech

Drug Trial Radar · NCT02694978

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Last checked: Nov 20, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,014 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,014

Actual

Start

Feb 29, 2016

Primary completion

Jan 16, 2017

Study completion Jul 17, 2017

Sponsor

Lead sponsor
AMAG Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).

Conditions

  • Iron Deficiency Anemia

Interventions

  • FerumoxytolDrug

  • FCMDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe HypotensionTime frame: Day 1 (after first dosing) through Week 5

Locations

127 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Huntsville, Alabama

  • Clinical Trial Site

    Tucson, Arizona

  • Clinical Trial Site

    Tucson, Arizona

  • Clinical Trial Site

    Anaheim, California

  • Clinical Trial Site

    Chula Vista, California

  • Clinical Trial Site

    Corona, California

  • Clinical Trial Site

    Encino, California

  • Clinical Trial Site

    Fountain Valley, California

  • Clinical Trial Site

    Granada Hills, California

  • Clinical Trial Site

    La Mesa, California

  • Clinical Trial Site

    Orange, California

  • Clinical Trial Site

    Oxnard, California

  • Clinical Trial Site

    Riverside, California

  • Clinical Trial Site

    San Diego, California

  • Clinical Trial Site

    West Hollywood, California

  • Clinical Trial Site

    Westminster, California

  • Clinical Trial Site

    Bristol, Connecticut

  • Clinical Trial Site

    Norwalk, Connecticut

  • Clinical Trial Site

    Clearwater, Florida

  • Clinical Trial Site

    Gainesville, Florida

  • Clinical Trial Site

    Lauderdale Lakes, Florida

  • Clinical Trial Site

    Lauderdale Lakes, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami Lakes, Florida

  • Clinical Trial Site

    North Miami, Florida

  • Clinical Trial Site

    South Miami, Florida

  • Clinical Trial Site

    West Palm Beach, Florida

  • Clinical Trial Site

    Winter Haven, Florida

  • Clinical Trial Site

    Atlanta, Georgia

  • Clinical Trial Site

    Augusta, Georgia

  • Clinical Trial Site

    Savannah, Georgia

  • Clinical Trial Site

    Thomasville, Georgia

  • Clinical Trial Site

    Elk Grove Village, Illinois

  • Clinical Trial Site

    Evergreen Park, Illinois

  • Clinical Trial Site

    Hazel Crest, Illinois

  • Clinical Trial Site

    Skokie, Illinois

  • Clinical Trial Site

    Skokie, Illinois

  • Clinical Trial Site

    Wichita, Kansas

  • Clinical Trial Site

    Crestview Hills, Kentucky

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.